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Kathryn B. Garber1,*Short-Term Impact of Direct-to-Consumer Testing
Like it or not, direct-to-consumer genetic analysis is widely
available to the general public, albeit at a significant out-of-
pocket cost. Whereas proponents argue that anybody
should be able to get their own genetic information and
that these tests could have a positive impact of health-
related behaviors, opponents say they lack clinical validity
and utility and may lead to increased anxiety and subse-
quent use of unnecessary screening procedures. Bloss
et al. surveyed more than 2000 individuals at baseline
and three months after receiving genetic risk information
for 22 conditions, based on the Navigenics Health
Compass, and found no evidence that direct-to-consumer
testing affects health-related behavior in the short-term.
The vast majority of subjects in the study (>90%) ex-
hibited no distress related to the genetic testing, but the
tests also didn’t have a positive impact on health behav-
iors, in that there was no change to dietary fat intake or
exercise behavior as a result of the genetic screen. There
also was no increase in the number of screening tests
completed by the time of first follow-up, although approx-
imately half of the subjects indicated their intent to do so.
One outcome that does need to be addressed is the fact that
10% of participants elected to consult a genetic counselor
in relation to their genetic profile, and greater than 25%
discussed the results with their physician. Certainly, the
healthcare system overall will need to be able to handle
this increased interest in genetics as more people opt for
genome-wide profiling.
Bloss et al. (2011). NEJM. Published online January 12,
2011. 10.1056/NEJMoa1011893.
Epimutations Could Make a Significant Contribution
to Cowden Syndrome
Mutations in PTEN cause the cancer-predisposing Cowden
syndrome, but a significant number of people who meet
the diagnostic criteria do not have a mutation in PTEN or
in SDHB or SDHD, which lead to a similar phenotype.
Even fewer people with Cowden-like syndrome, who
have features of Cowden syndrome but do not meet the
diagnostic criteria, have documented mutations in these
genes. Because epigenetic alterations are known to play
a role in cancer development and progression, Bennett
et al. collected a group of patients with Cowden syndrome
and Cowden-like syndrome in whommutations could not
be found. Hypermethylation upstream of PTEN was docu-1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americamented in peripheral lymphocytes from 45 of 123 individ-
uals, but, unexpectedly, this was not associated with
decreased PTEN expression. Instead, themethylation influ-
enced expression of KILLIN, a gene that shares a transcrip-
tional start site with PTEN but is transcribed in the
opposite direction. In addition to implicating a new gene
in Cowden syndrome, if these results hold up, it would
alter the scheme for genetic testing in patients, particularly
those with Cowden-like syndrome, because KILLIN meth-
ylation accounts for a larger fraction of these patients
than do PTEN mutations.
Bennett et al. (2010). JAMA 304: 2724–2732. 10.1001/
jama.2010.1877.Sequencing the Future
When there are limits to the amounts of DNA that can be
genotyped for a reasonable cost, we target genetic screens
to the people most likely to carry a mutation. That’s the
rationale behind the targeting of certain carrier screens,
including cystic fibrosis to those of European descent and
Tay-Sachs disease to those of Ashkenazi Jewish descent.
Indeed, we not only focus these screens on particular pop-
ulations, we also limit the screens to particular disease
mutations in that population. These limitations mean
that some carriers are missed and many severe recessive
disorders go unscreened. What happens when we aren’t
as hampered by technological limitations? Bell et al.
show that you can create screens that identify carriers for
more than 400 severe recessive childhood disorders. More-
over, their screen uses target enrichment and next genera-
tion sequencing techniques, so the screens detect most
relevant mutations, rather than a hand-picked subset.
Although this screening approach highlights the potential
future of carrier screening, it also sheds light on potential
kinks for its use in populations. Of the sequence variants
flagged as disease mutations by their filtering criteria,
74% of them turned out to be polymorphisms. Even the
fact that amutation was cited in the literature did not guar-
antee it was one; in fact 27% of cited disease mutations
were found to be likely polymorphisms or to be misanno-
tated. Thus, as with other genomics applications, the trick
now lies in interpretation rather than in production of
sequence.
Bell et al. (2011). Science Translational Medicine, 3: 65ra4.
10.1126/scitranslmed.3001756.ta, GA 30322, USA
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Did HTR2B Make Them Do It?
Recent work by Bevilacqua et al. argues that a nonsense
codon in HTR2B, which normally encodes a subtype of
serotonin receptor, is found at higher rates in a set of violent
criminals from Finland, and they attribute this to increased
impulsivity in carriers of the allele. The ‘‘impulsivity’’ allele
is so far only found in Finland, and the authors extrapolate
that there are 100,000 carriers in Finland. Finland is not
exactly known as a hot-bed of criminal and rash behavior,
so the lack of impulse control because of this mutation, if
there is any, is not strongly penetrant. One environmental
contributor that could influence its phenotypic expression
is alcohol; in their original association study, almost all of
the crimes committed by the carriers of the nonsense
HTR2B allele occurred when the individuals were under
the influence of alcohol. Particularly given historical
missteps in declaring ‘‘criminality genotypes,’’ caution
must be urged in the interpretation of this work.
Bevilacqua et al. (2010). Nature 468: 1061–1066. 10.1038/
nature09629.
Two MicroRNAs Responsible for Delayed Hemoglobin
Switching in Trisomy 13
Because of the many genes involved and the complexity of
the resulting phenotypes, it can be difficult to attribute any
one component of an aneuploidy syndrome to a culprit126 The American Journal of Human Genetics 88, 125–126, Februarygene or genes. Careful comparisons of phenotype and
the chromosomal composition of individuals with partial
aneuploidy for a particular chromosome can sometimes
limit the relevant chromosome region, but—even so—
the resulting list of candidate genes can be too long to
wade through. One feature of the trisomy 13 phenotype
is the delayed switch to and persistence of fetal hemo-
globin (HbF). Through use of a bioinformatics approach,
Sankaran et al. implicate two microRNAs on chromosome
13 as being key to this process, and further investigation of
their target gene leads them to expand the description of
the hematopoietic phenotype caused by trisomy 13. Anal-
ysis of potential targets for these miRNAs, miR-15a and
miR-16-1, leads them toMYB, which is a negative regulator
of HbF expression and is also crucial for normal differenti-
ation kinetics of adult erythroid cells. This led Sankararn
et al. to examine histological samples from individuals
with trisomy 13 and to discover a previously unrecognized
aspect of the phenotype: a dramatic elevation in the
number of megakaryocytes, which also had an abnormal
nuclear morphology. Beyond informing our under-
standing of the trisomy 13 phenotype, we now better
understand the regulation of erythroid differentiation
and globin gene expression.
Sankaran et al. (2011). PNAS. Published online January, 4,
2011. 10.1073/pnas.1018384108.This Month in our Sister JournalsPerinatal Lethal Osteogenesis Imperfecta: Will It
Happen Again?
Both autosomal dominant and autosomal recessive forms
of perinatal lethal osteogenesis imperfecta (OI) have been
documented, and this complicates genetic counseling for
families who have had an affected infant. The recurrence
risks in these families can range from extremely low, in
the case of a new dominant mutation, up to 50% if one of
the parents is mosaic for a dominant mutation. Pyott et al.
use data collected over the course of several years to better
calculate recurrence risks for different categories. In 16%
of cases that were due to a dominant mutation in one of
the type I collagen genes, parental somatic mosaicism was
documented, leaving these families at much higher recur-rence risk than the general recurrence estimate of 1.3%after
the birth of a first affected child. An additional sample of
families with more than one affected pregnancy allows
them to demonstrate that parental mosaicism of a domi-
nant mutation is a more common cause of familial recur-
rence than are autosomal recessive mutations. In this
sample, the recurrence risk in families with parental mosai-
cism turns out to be 27%, which is very close to the 31%
recurrence riskobserved in familieswithOIbecauseof reces-
sivemutations.Mutation identification in affected children
and analysis of parental samples can help to assign families
to different categories for more accurate risk assessment.
Pyott et al. (2011) Genetics in Medicine. Published online
January 13, 2011. 10.1097/GIM.0b013e318202e0f6.11, 2011
